Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok
Journal of Clinical Oncology (2015) Vol. 33, Iss. 17, pp. 1974-1982
Open Access | Times Cited: 2435

Showing 26-50 of 2435 citing articles:

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, et al.
Investigational New Drugs (2016) Vol. 35, Iss. 2, pp. 180-188
Open Access | Times Cited: 738
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens, Gary Middleton
Cancer Immunology Research (2015) Vol. 3, Iss. 5, pp. 436-443
Open Access | Times Cited: 728
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Dirix, István Takács, Guy Jérusalem, et al.
Breast Cancer Research and Treatment (2017) Vol. 167, Iss. 3, pp. 671-686
Open Access | Times Cited: 670
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, et al.
British Journal of Cancer (2020) Vol. 122, Iss. 11, pp. 1630-1637
Open Access | Times Cited: 657
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim, Chia‐Wei Li, Weiya Xia, et al.
Cancer Cell (2016) Vol. 30, Iss. 6, pp. 925-939
Open Access | Times Cited: 652
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
Martin Reck, Klaus F. Rabe
New England Journal of Medicine (2017) Vol. 377, Iss. 9, pp. 849-861
Closed Access | Times Cited: 641
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Jia‐Ren Lin, Benjamin Izar, Shu Wang, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 620
Tumour-targeting bacteria engineered to fight cancer
Shibin Zhou, Claudia Gravekamp, David Bermudes, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 12, pp. 727-743
Open Access | Times Cited: 620
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama, Zhiqiang An
Protein & Cell (2016) Vol. 9, Iss. 1, pp. 33-46
Open Access | Times Cited: 618
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel, Christian Posch, Steven R. Barthel, et al.
Cell (2015) Vol. 162, Iss. 6, pp. 1242-1256
Open Access | Times Cited: 589
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal, Jasper Z. Williams, Leonardo Morsut, et al.
Cell (2016) Vol. 167, Iss. 2, pp. 419-432.e16
Open Access | Times Cited: 584
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Seungwon Yang, Jiangbo Wei, Yan‐Hong Cui, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 579
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar, Kristen A. Marrone, Megan L. Troxell, et al.
Kidney International (2016) Vol. 90, Iss. 3, pp. 638-647
Open Access | Times Cited: 576
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 19, pp. 2117-2124
Open Access | Times Cited: 563
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002435-e002435
Open Access | Times Cited: 553
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 2, pp. 226-235
Open Access | Times Cited: 543
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott
Clinical Therapeutics (2015) Vol. 37, Iss. 4, pp. 764-782
Open Access | Times Cited: 533
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 4, pp. 521-536
Open Access | Times Cited: 527
Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy
Kuangda Lu, Chunbai He, Nining Guo, et al.
Nature Biomedical Engineering (2018) Vol. 2, Iss. 8, pp. 600-610
Closed Access | Times Cited: 518
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 3, pp. 255-289
Open Access | Times Cited: 515
Dermatologic Reactions to Immune Checkpoint Inhibitors
V. Sibaud
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 345-361
Closed Access | Times Cited: 503
GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation
Burkhard Becher, Sònia Tugues, Melanie Greter
Immunity (2016) Vol. 45, Iss. 5, pp. 963-973
Open Access | Times Cited: 479
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Haidong Tang, Yong Liang, Robert A. Anders, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 580-588
Open Access | Times Cited: 465
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Dmitrij Ostroumov, Nora Fekete-Drimusz, Michael Saborowski, et al.
Cellular and Molecular Life Sciences (2017) Vol. 75, Iss. 4, pp. 689-713
Open Access | Times Cited: 462
International Consensus Guidance for Management of Myasthenia Gravis
Pushpa Narayanaswami, Donald B. Sanders, Gil I. Wolfe, et al.
Neurology (2020) Vol. 96, Iss. 3, pp. 114-122
Open Access | Times Cited: 460

Scroll to top